Neuralgia trigeminal (NT) é um tipo de dor neuropática orofacial intensa e debilitante sentida ao longo do nervo trigêmeo. Seu diagnóstico é meramente clínico, sem exames específicos, o que dificulta a presteza e eficácia do tratamento. O sintoma mais característico é alodínia mecânica relacionada à sensibilização central. Seu tratamento é farmacológico e/ou cirúrgico, no entanto pode trazer poucos benefícios e/ou importantes efeitos colaterais sem a garantia de remissão total dos sintomas. No tratamento farmacológico, os anticonvulsivantes são fármacos de primeira linha de tratamento, mas também são obtidas respostas de melhora com o uso de fármacos ansiolíticos e opioides. A dificuldade no tratamento da NT se deve, em parte, à falta de compreensão dos mecanismos envolvidos na geração da dor; sendo, desta forma, imprescindível a busca de um melhor entendimento da fisiopatologia da NT buscando identificar as vias envolvidas no processo de dor. Sendo assim, o objetivo deste estudo foi avaliar o possível envolvimento das vias gabaérgica, glutamatérgica e opioidérgica na fisiopatogenia de um modelo de neuralgia trigeminal em ratos. A resposta nociceptiva dos animais foi avaliada por meio do teste de von Frey eletrônicoantes e após a administração de agonistas gabaérgicos e opioidérgico e de antagonista glutamatérgico. Além da a resposta nociceptiva, foram avaliados os níveis de fator neurotrófico derivado do cérebro (BDNF) em gânglio trigeminal, tronco encefálico e córtex pré-frontal. Todos os procedimentos experimentais foram realizados na Unidade de Experimentação Animal (UEA), Unidade de Análises Moleculares e de Proteínas (UAMP) do Hospital de Clínicas de Porto Alegre (HCPA). A indução da dor neuropática foi por constrição crônica do nervo infraorbitário (CCI-ION) proposto por Imamura em 1997 adaptado (Imamura Y., Kawamoto H., Nakanishi O. Charactherization of heat-hiperalgesia in experimental trigeminal neuropathy in rats. Exp Brain Res, 1997; 116: 97-103.). Para isso foram utilizados 112 ratos Wistar, machos divididos para o procedimento cirúrgico em 3 grupos: Controle Total, Dor e Sham. Quatorze dias após o procedimento cirúrgico, tempo necessário para o desenvolvimento da dor neuropática, realizamos dois protocolos e dividimos os grupos em: protocolo 1: controle veículo, cirurgia sham veículo, cirurgia sham agonista benzodiazepínico, cirurgia sham antagonista glutamatérgico, dor veículo, dor agonista benzodiazepínico, dor antagonista glutamatérgico; protocolo 2: controle veículo, cirurgia sham veículo, cirurgia sham agonista gabaérgico, cirurgia sham agonista opioidérgico, dor veículo, dor agonista gabaérgico, dor agonista opioidérgico. Os animais dos grupos sham sofreram apenas incisão cirúrgica, sem constrição do nervo. Durante o procedimento cirúrgico a indução anestésica foi feita com cetamina (50mg/kg) e xilazina (5mg/kg) e a manutenção, com isoflurano 2-3%. O controle da dor pós-operatória foi obtido com cloridrato de tramadol (10mg/kg) no intervalo de 12h por 48h. A resposta hiperalgésica mecânica (von Frey) foi avaliada antes da indução do modelo (medida basal), 7 e 14 dias após cirurgia, pré-administração dos fármacos, 15,30 e 60 minutos após administração dos fármacos: veículo - solução salina; agonista benzodiazepínico – diazepam (2 mg/kg); antagonista glutamatérgico - MK- 801 (0,25mg/Kg), agonista opioidérgico – morfina (5,0 mg/kg) e agonista gabaérgico – fenobarbital (100mg/kg). Os dados foram analisados por Equações Estimativas Generalizadas e expressos em média+EPM. Todos os procedimentos foram aprovados pelo CEUA/HCPA e CEUA/UFRGS sob número: 14-0604 e 29310, respectivamente. Inicialmente foram realizados testes para verificação do modelo de dor, foi observado que 14 dias após cirurgia de constrição do nervo infraorbitário, os animais do grupo dor apresentaram redução nos limiares de retirada da face no teste de von Frey facial comparado aos grupos controle e sham [GEE: interação grupo x tempo (Waldχ2=15,81; 2, P<0,05)]. Após o estabelecimento do modelo, foram realizados testes nociceptivos para avaliação das vias envolvidas na neuralgia trigeminal, observou-se interação grupo x tempo (Wald _2=175,74;18, P<0,01). No protocolo 1, os animais do grupo dor que receberam agonista benzodiazepínico (diazepam) apresentaram aumento no limiar nociceptivo a partir de 15 minutos após administração e este resultado permaneceu por até 60 minutos. Os animais do grupo dor que receberam antagonista glutamatérgico (MK-801) apresentaram aumento no limiar de retirada da face somente na avaliação realizada 60 minutos após a administração do fármaco. No protocolo 2, análise estatística mostrou interação entre as variáveis tempo x grupo (Wald χ2=657,53;18, P<0,01), os animais do grupo dor que receberam fenobarbital apresentaram aumento no limiar nociceptivo a partir de 15 minutos após administração e este resultado permaneceu por até 60 minutos. Por outro lado, os animais que receberam morfina apresentaram um aumento no limiar nociceptivo significativamente maior que os animais que receberam fenobarbital, no entanto ambos os fármacos reverteram a hiperalgesia induzida pela exposição ao modelo de dor. Na análise bioquímica, em córtex e tronco encefálico foi observado aumento nos níveis de BDNF tanto nos animais submetidos ao modelo de NT quanto aos que foram expostos a cirurgia sham (ANOVA de uma via/SNK, F(2,22)=13,46; F(2,25)=6,08, P<0,05, respectivamente. Em nível periférico foi observado aumento nos níveis de BDNF em gânglio trigeminal nos animais submetidos ao modelo de NT (ANOVA de uma via/SNK,F(2,22)=4,09; P<0,05). Em soro não foi observada diferença nos níveis de BDNF entre os grupos (ANOVA de uma via, P>0,05). Com base nos resultados encontrados, este estudo sugere que há o envolvimento das vias gabaérgica, glutamatérgica e opioidergica no processamento da dor neuropática orofacial (neuralgia trigeminal) sugerindo que há funcionalidade dos receptores testados. No entanto, estes agonistas gabaérgicos não induziram analgesia nos animais controles e cirurgia sham sugerindo uma alteração na liberação ou na síntese de GABA nos animais com NT. Neste estudo, não foram realizadas análises de expressão e quantificação de receptores, apenas avaliou-se a resposta nociceptiva e os níveis de BDNF centrais e periféricos. De acordo com estes achados a via gabaérgica teve uma resposta mais rápida que a via glutamatérgica. Alguns estudos demonstram que os receptores glutamatérgicos estão localizados em fibras não mielinizadas na periferia isto pode justificar o atraso na resposta dos animais que receberam antagonista glutamatérgico em nosso estudo. Quanto aos níveis de BDNF observamos que há um aumento desta neurotrofina nos animais submetidos ao modelo de NT sugerindo um envolvimento deste neuromodulador em eventos neuroplásticos da NT. / Trigeminal neuralgia (TN) is a type of intense and debilitating orofacial neuropathic pain felt along the trigeminal nerve. The diagnosis is purely clinical, without specific tests, which makes the promptness and effectiveness of treatment. The most characteristic symptom is mechanical allodynia related to central sensitization. Its treatment is pharmacological and / or surgical treatment, however can bring few benefits and / or significant side effects without the guarantee of complete remission of symptoms. In drug treatment, the anticonvulsant drug are first-line treatment, but also enhances responses are obtained with the use of anxiolytic drugs and opioids. The difficulty in treating NT is due in part to the lack of understanding of the mechanisms involved in the generation of pain; It is thus essential to search for a better understanding of the pathophysiology NT seeking to identify the pathways involved in pain process. Thus, the aim of this study was to evaluate the possible involvement of GABAergic pathways, glutamatergic and opioidergic in the pathogenesis of a model of trigeminal neuralgia in rats. The nociceptive response of the animals was assessed using the von Frey test eletrônicoantes and after administration of opioid agonists and GABAergic and glutamatergic antagonist. In the nociceptive response was evaluated derived neurotrophic factor levels in the brain (BDNF) in the trigeminal ganglia, brainstem, and prefrontal cortex. All experimental procedures were performed in the Animal Experimentation Unit (UEA), Unit of Analysis and Molecular Protein (UAMP) Porto Alegre Clinical Hospital (HCPA). The induction of neuropathic pain was by chronic constriction of the infraorbital nerve (CCI-ION) proposed by Imamura in 1997 adapted. For that they were used 112 male Wistar rats divided into the surgical procedure into 3 groups: Full Control, Pain and Sham. Fourteen days after surgery, time required for the development of neuropathic pain, performed two protocols and divided groups: Protocol 1: vehicle control, sham surgery vehicle, sham surgery benzodiazepine agonist, sham surgery glutamatergic antagonist, vehicle pain, agonist benzodiazepine pain and antagonist glutamatergic pain. Protocol 2: vehicle control, vehicle sham surgery, sham surgery gabaergic agonist, sham surgery opioid agonist, vehicle pain, gabaergic agonist pain, opioid agonist pain. The animals of the sham group underwent only surgical incision without nerve constriction. During surgery anesthesia was induced with ketamine (50 mg / kg) and xylazine (5 mg / kg) and maintained with isoflurane 2-3%. The control of postoperative pain has been obtained with tramadol hydrochloride (10mg / kg) at 12h intervals for 48 hours. The mechanical hyperalgesic response (von Frey) was assessed before induction model (baseline measurement), 7 and 14 days after surgery, pre-administration of drugs, 15,30 and 60 minutes after drug administration: Vehicle - saline; benzodiazepine agonist - diazepam (2 mg / kg); glutamatergic antagonist - MK-801 (0.25mg / kg), opioid agonist - Morphine (5.0 mg / kg) and gabaergic agonist - phenobarbital (100 mg / kg). Data were analyzed by Equation Generalised Estimates and expressed as mean ± SEM. All procedures were approved by CEUA / HCPA and CEUA / UFRGS under number: 14-0604 and 29310, respectively. Initially tests were carried out to verify the pain model, it was observed that 14 days after infraorbital nerve constriction surgery, animals pain group showed a reduction in the face withdrawal thresholds to von Frey facial test compared to control and sham groups [ GEE: group x time interaction (Wald 2 = 15.81; 2, P <0.05)]. After the model category, nociceptive tests were performed to assess the pathways involved in the trigeminal neuralgia, observed group x time interaction (Wald _2 = 175.74; 18 P <0.01). In protocol 1, the animals in the group who received pain benzodiazepine agonist (diazepam) showed an increase in nociceptive threshold from 15 minutes after administration and this result remained for up to 60 minutes. Animals of group pain that received glutamate antagonist (MK-801) showed an increase in the withdrawal threshold of the face only in the assessment was performed 60 minutes after drug administration. In protocol 2, statistical analysis showed interaction between the variables time x group (Wald χ2 = 657.53; 18, P <0.01), the animals showed increased nociceptive threshold from 15 minutes after administration of phenobarbital and morphine and this result remained for up to 60 minutes. On the other hand, animals receiving morphine showed an increased nociceptive threshold significantly higher in the animals receiving phenobarbital, however both drugs reversed hyperalgesia induced by exposure to pain model. In biochemical analysis, cortex and brainstem was observed increase in BDNF levels in both animals subjected to NT model and those who were exposed to sham surgery (one-way ANOVA / SNK, F (2,22) = 13.46 ;. F (2,25) = 6.08, P <0.05, respectively, at the peripheral level increase was observed in BDNF levels in trigeminal ganglion of animals subjected to the NT model (one-way ANOVA / SNK F ( 2,22) = 4.09; P <. 0.05). In serum was no difference in BDNF levels between groups (one-way ANOVA, P> 0.05) based on the results, this study. suggests that there is involvement of gabaergic pathways, glutamatergic and opioidergic processing orofacial neuropathic pain (trigeminal neuralgia) suggesting that there is functionality of the tested receptors. However, these GABAergic agonists did not induce analgesia in control animals and sham surgery suggesting a change in release or GABA synthesis in animals with NT. in this study, were not realized expression analysis and quantification of receptors, only evaluated the nociceptive response and the central and peripheral levels of BDNF. According to these findings, gabaergic pathways had a faster response than glutamatergic pathways. Some studies have shown that glutamate receptors are located in non-myelinated fibers in the periphery that can justify the delay in the animals that received glutamatergic antagonist in our study. As for BDNF levels we observed that there is an increase of this neurotrophin in animals subjected to NT model suggesting an involvement of this neuromodulator in neuroplastic events NT.

Neuralgia trigeminal (NT) é um tipo de dor neuropática orofacial intensa e debilitante sentida ao longo do nervo trigêmeo. Seu diagnóstico é meramente clínico, sem exames específicos, o que dificulta a presteza e eficácia do tratamento. O sintoma mais característico é alodínia mecânica relacionada à sensibilização central. Seu tratamento é farmacológico e/ou cirúrgico, no entanto pode trazer poucos benefícios e/ou importantes efeitos colaterais sem a garantia de remissão total dos sintomas. No tratamento farmacológico, os anticonvulsivantes são fármacos de primeira linha de tratamento, mas também são obtidas respostas de melhora com o uso de fármacos ansiolíticos e opioides. A dificuldade no tratamento da NT se deve, em parte, à falta de compreensão dos mecanismos envolvidos na geração da dor; sendo, desta forma, imprescindível a busca de um melhor entendimento da fisiopatologia da NT buscando identificar as vias envolvidas no processo de dor. Sendo assim, o objetivo deste estudo foi avaliar o possível envolvimento das vias gabaérgica, glutamatérgica e opioidérgica na fisiopatogenia de um modelo de neuralgia trigeminal em ratos. A resposta nociceptiva dos animais foi avaliada por meio do teste de von Frey eletrônicoantes e após a administração de agonistas gabaérgicos e opioidérgico e de antagonista glutamatérgico. Além da a resposta nociceptiva, foram avaliados os níveis de fator neurotrófico derivado do cérebro (BDNF) em gânglio trigeminal, tronco encefálico e córtex pré-frontal. Todos os procedimentos experimentais foram realizados na Unidade de Experimentação Animal (UEA), Unidade de Análises Moleculares e de Proteínas (UAMP) do Hospital de Clínicas de Porto Alegre (HCPA). A indução da dor neuropática foi por constrição crônica do nervo infraorbitário (CCI-ION) proposto por Imamura em 1997 adaptado (Imamura Y., Kawamoto H., Nakanishi O. Charactherization of heat-hiperalgesia in experimental trigeminal neuropathy in rats. Exp Brain Res, 1997; 116: 97-103.). Para isso foram utilizados 112 ratos Wistar, machos divididos para o procedimento cirúrgico em 3 grupos: Controle Total, Dor e Sham. Quatorze dias após o procedimento cirúrgico, tempo necessário para o desenvolvimento da dor neuropática, realizamos dois protocolos e dividimos os grupos em: protocolo 1: controle veículo, cirurgia sham veículo, cirurgia sham agonista benzodiazepínico, cirurgia sham antagonista glutamatérgico, dor veículo, dor agonista benzodiazepínico, dor antagonista glutamatérgico; protocolo 2: controle veículo, cirurgia sham veículo, cirurgia sham agonista gabaérgico, cirurgia sham agonista opioidérgico, dor veículo, dor agonista gabaérgico, dor agonista opioidérgico. Os animais dos grupos sham sofreram apenas incisão cirúrgica, sem constrição do nervo. Durante o procedimento cirúrgico a indução anestésica foi feita com cetamina (50mg/kg) e xilazina (5mg/kg) e a manutenção, com isoflurano 2-3%. O controle da dor pós-operatória foi obtido com cloridrato de tramadol (10mg/kg) no intervalo de 12h por 48h. A resposta hiperalgésica mecânica (von Frey) foi avaliada antes da indução do modelo (medida basal), 7 e 14 dias após cirurgia, pré-administração dos fármacos, 15,30 e 60 minutos após administração dos fármacos: veículo - solução salina; agonista benzodiazepínico – diazepam (2 mg/kg); antagonista glutamatérgico - MK- 801 (0,25mg/Kg), agonista opioidérgico – morfina (5,0 mg/kg) e agonista gabaérgico – fenobarbital (100mg/kg). Os dados foram analisados por Equações Estimativas Generalizadas e expressos em média+EPM. Todos os procedimentos foram aprovados pelo CEUA/HCPA e CEUA/UFRGS sob número: 14-0604 e 29310, respectivamente. Inicialmente foram realizados testes para verificação do modelo de dor, foi observado que 14 dias após cirurgia de constrição do nervo infraorbitário, os animais do grupo dor apresentaram redução nos limiares de retirada da face no teste de von Frey facial comparado aos grupos controle e sham [GEE: interação grupo x tempo (Waldχ2=15,81; 2, P<0,05)]. Após o estabelecimento do modelo, foram realizados testes nociceptivos para avaliação das vias envolvidas na neuralgia trigeminal, observou-se interação grupo x tempo (Wald _2=175,74;18, P<0,01). No protocolo 1, os animais do grupo dor que receberam agonista benzodiazepínico (diazepam) apresentaram aumento no limiar nociceptivo a partir de 15 minutos após administração e este resultado permaneceu por até 60 minutos. Os animais do grupo dor que receberam antagonista glutamatérgico (MK-801) apresentaram aumento no limiar de retirada da face somente na avaliação realizada 60 minutos após a administração do fármaco. No protocolo 2, análise estatística mostrou interação entre as variáveis tempo x grupo (Wald χ2=657,53;18, P<0,01), os animais do grupo dor que receberam fenobarbital apresentaram aumento no limiar nociceptivo a partir de 15 minutos após administração e este resultado permaneceu por até 60 minutos. Por outro lado, os animais que receberam morfina apresentaram um aumento no limiar nociceptivo significativamente maior que os animais que receberam fenobarbital, no entanto ambos os fármacos reverteram a hiperalgesia induzida pela exposição ao modelo de dor. Na análise bioquímica, em córtex e tronco encefálico foi observado aumento nos níveis de BDNF tanto nos animais submetidos ao modelo de NT quanto aos que foram expostos a cirurgia sham (ANOVA de uma via/SNK, F(2,22)=13,46; F(2,25)=6,08, P<0,05, respectivamente. Em nível periférico foi observado aumento nos níveis de BDNF em gânglio trigeminal nos animais submetidos ao modelo de NT (ANOVA de uma via/SNK,F(2,22)=4,09; P<0,05). Em soro não foi observada diferença nos níveis de BDNF entre os grupos (ANOVA de uma via, P>0,05). Com base nos resultados encontrados, este estudo sugere que há o envolvimento das vias gabaérgica, glutamatérgica e opioidergica no processamento da dor neuropática orofacial (neuralgia trigeminal) sugerindo que há funcionalidade dos receptores testados. No entanto, estes agonistas gabaérgicos não induziram analgesia nos animais controles e cirurgia sham sugerindo uma alteração na liberação ou na síntese de GABA nos animais com NT. Neste estudo, não foram realizadas análises de expressão e quantificação de receptores, apenas avaliou-se a resposta nociceptiva e os níveis de BDNF centrais e periféricos. De acordo com estes achados a via gabaérgica teve uma resposta mais rápida que a via glutamatérgica. Alguns estudos demonstram que os receptores glutamatérgicos estão localizados em fibras não mielinizadas na periferia isto pode justificar o atraso na resposta dos animais que receberam antagonista glutamatérgico em nosso estudo. Quanto aos níveis de BDNF observamos que há um aumento desta neurotrofina nos animais submetidos ao modelo de NT sugerindo um envolvimento deste neuromodulador em eventos neuroplásticos da NT. / Trigeminal neuralgia (TN) is a type of intense and debilitating orofacial neuropathic pain felt along the trigeminal nerve. The diagnosis is purely clinical, without specific tests, which makes the promptness and effectiveness of treatment. The most characteristic symptom is mechanical allodynia related to central sensitization. Its treatment is pharmacological and / or surgical treatment, however can bring few benefits and / or significant side effects without the guarantee of complete remission of symptoms. In drug treatment, the anticonvulsant drug are first-line treatment, but also enhances responses are obtained with the use of anxiolytic drugs and opioids. The difficulty in treating NT is due in part to the lack of understanding of the mechanisms involved in the generation of pain; It is thus essential to search for a better understanding of the pathophysiology NT seeking to identify the pathways involved in pain process. Thus, the aim of this study was to evaluate the possible involvement of GABAergic pathways, glutamatergic and opioidergic in the pathogenesis of a model of trigeminal neuralgia in rats. The nociceptive response of the animals was assessed using the von Frey test eletrônicoantes and after administration of opioid agonists and GABAergic and glutamatergic antagonist. In the nociceptive response was evaluated derived neurotrophic factor levels in the brain (BDNF) in the trigeminal ganglia, brainstem, and prefrontal cortex. All experimental procedures were performed in the Animal Experimentation Unit (UEA), Unit of Analysis and Molecular Protein (UAMP) Porto Alegre Clinical Hospital (HCPA). The induction of neuropathic pain was by chronic constriction of the infraorbital nerve (CCI-ION) proposed by Imamura in 1997 adapted. For that they were used 112 male Wistar rats divided into the surgical procedure into 3 groups: Full Control, Pain and Sham. Fourteen days after surgery, time required for the development of neuropathic pain, performed two protocols and divided groups: Protocol 1: vehicle control, sham surgery vehicle, sham surgery benzodiazepine agonist, sham surgery glutamatergic antagonist, vehicle pain, agonist benzodiazepine pain and antagonist glutamatergic pain. Protocol 2: vehicle control, vehicle sham surgery, sham surgery gabaergic agonist, sham surgery opioid agonist, vehicle pain, gabaergic agonist pain, opioid agonist pain. The animals of the sham group underwent only surgical incision without nerve constriction. During surgery anesthesia was induced with ketamine (50 mg / kg) and xylazine (5 mg / kg) and maintained with isoflurane 2-3%. The control of postoperative pain has been obtained with tramadol hydrochloride (10mg / kg) at 12h intervals for 48 hours. The mechanical hyperalgesic response (von Frey) was assessed before induction model (baseline measurement), 7 and 14 days after surgery, pre-administration of drugs, 15,30 and 60 minutes after drug administration: Vehicle - saline; benzodiazepine agonist - diazepam (2 mg / kg); glutamatergic antagonist - MK-801 (0.25mg / kg), opioid agonist - Morphine (5.0 mg / kg) and gabaergic agonist - phenobarbital (100 mg / kg). Data were analyzed by Equation Generalised Estimates and expressed as mean ± SEM. All procedures were approved by CEUA / HCPA and CEUA / UFRGS under number: 14-0604 and 29310, respectively. Initially tests were carried out to verify the pain model, it was observed that 14 days after infraorbital nerve constriction surgery, animals pain group showed a reduction in the face withdrawal thresholds to von Frey facial test compared to control and sham groups [ GEE: group x time interaction (Wald 2 = 15.81; 2, P <0.05)]. After the model category, nociceptive tests were performed to assess the pathways involved in the trigeminal neuralgia, observed group x time interaction (Wald _2 = 175.74; 18 P <0.01). In protocol 1, the animals in the group who received pain benzodiazepine agonist (diazepam) showed an increase in nociceptive threshold from 15 minutes after administration and this result remained for up to 60 minutes. Animals of group pain that received glutamate antagonist (MK-801) showed an increase in the withdrawal threshold of the face only in the assessment was performed 60 minutes after drug administration. In protocol 2, statistical analysis showed interaction between the variables time x group (Wald χ2 = 657.53; 18, P <0.01), the animals showed increased nociceptive threshold from 15 minutes after administration of phenobarbital and morphine and this result remained for up to 60 minutes. On the other hand, animals receiving morphine showed an increased nociceptive threshold significantly higher in the animals receiving phenobarbital, however both drugs reversed hyperalgesia induced by exposure to pain model. In biochemical analysis, cortex and brainstem was observed increase in BDNF levels in both animals subjected to NT model and those who were exposed to sham surgery (one-way ANOVA / SNK, F (2,22) = 13.46 ;. F (2,25) = 6.08, P <0.05, respectively, at the peripheral level increase was observed in BDNF levels in trigeminal ganglion of animals subjected to the NT model (one-way ANOVA / SNK F ( 2,22) = 4.09; P <. 0.05). In serum was no difference in BDNF levels between groups (one-way ANOVA, P> 0.05) based on the results, this study. suggests that there is involvement of gabaergic pathways, glutamatergic and opioidergic processing orofacial neuropathic pain (trigeminal neuralgia) suggesting that there is functionality of the tested receptors. However, these GABAergic agonists did not induce analgesia in control animals and sham surgery suggesting a change in release or GABA synthesis in animals with NT. in this study, were not realized expression analysis and quantification of receptors, only evaluated the nociceptive response and the central and peripheral levels of BDNF. According to these findings, gabaergic pathways had a faster response than glutamatergic pathways. Some studies have shown that glutamate receptors are located in non-myelinated fibers in the periphery that can justify the delay in the animals that received glutamatergic antagonist in our study. As for BDNF levels we observed that there is an increase of this neurotrophin in animals subjected to NT model suggesting an involvement of this neuromodulator in neuroplastic events NT.

A sinalização muscarínica exerce função modulatória sobre diferentes aspectos da cognição e emoções. Todos os cinco subtipos de receptores muscarínicos (mAChR), M1 a M5, são expressos no hipocampo de mamíferos e são ativados de forma sobreposta pela maioria dos fármacos, dificultando avanços significativos na compreensão da contribuição de cada componente desse sistema. A toxina muscarínica 3 (MT3) é um antagonista seletivo para o subtipo M4, permitindo a investigação das ações modulatórias deste receptor no aprendizado, memória e plasticidade sináptica. Os M4 são receptores acoplados à proteína G (GPCRs) que atuam via Gi/o desencadeando efeitos inibitórios sobre as células em que estão presentes. Estudos comportamentais anteriores indicam que a administração de MT3 imediatamente após o treino em uma tarefa aversiva produz efeito amnéstico, enquanto que a administração antes da evocação, causa facilitação. Uma explicação para estes resultados é que os circuitos locais envolvidos na consolidação e na evocação da memória diferem em sua natureza. Nesse contexto, sugere-se que o efeito amnéstico da MT3 sobre a consolidação seja consequência da supressão da inibição de interneurônios GABAérgicos; enquanto que na evocação, esse efeito se daria sobre as sinapses glutamatérgicas. Assim, no presente trabalho, com o objetivo de investigar como o receptor M4 modula a plasticidade sináptica de longa duração e interage com uma dessas sinalizações, no caso a GABAérgica, utilizou-se a técnica de eletrofisiologia in vivo de hipocampo de ratos anestesiados. Para tanto, foram realizados registros extracelulares do potencial excitatório pós-sináptico de campo (fEPSP) de CA1 evocados por estimulação contralateral da via Colateral de Schaffer com infusão dos fármacos 15 min antes ou depois da estimulação elétrica de alta ou baixa frequência (HFS: 10 trens 0,5 Hz, 20 pulsos 100 Hz; ou LFS: 600 pulsos 1 Hz, respectivamente). MT3 (4,0 μg/μl), bicuculina (0,06 μg/μl), baclofen (0,2 μg/μl) e veículo, isoladamente ou combinados, não alteraram a amplitude da resposta evocada basal ou a facilitação por pulso pareado (FPP) 15 min após a infusão. MT3 aparentemente atenuou, mas não de forma significativa, a potenciação de longa duração (LTP) em relação ao controle (potenciação 60 min após a HFS de 31,8% e 66,0%, respectivamente). Além disso, não houve diferença significativa entre a amplitude do fEPSP no período basal e 60 min após a HFS sob ação da MT3. Bicuculina, embora não tenha abolido a LTP e nem causado alteração na FPP, produziu uma potenciação de apenas 36,4%. Baclofen promoveu uma potenciação semelhante à dos controles. A administração de baclofen também reduziu significativamente a FPP em relação ao basal. A administração conjunta de MT3 com bicuculina ou baclofen promoveu uma potenciação semelhante ao controle. MT3 não apresentou efeito sobre a manutenção da LTP quando aplicada 15 min após a HFS. Por fim, não foi possível induzir a depressão de longa duração (LTD) com o protocolo de LFS utilizado. Embora não tenha ocorrido diferença estatisticamente significativa entre os grupos devido ao baixo número de animais utilizados, os dados sugerem a possibilidade de uma amplitude reduzida da LTP quando da injeção de bicuculina. Baclofen alterou a FPP em relação ao fEPSP basal, o mesmo não tendo sido observado no grupo controle. Com a administração concomitante de MT3, tais alterações deixam de ser identificadas. Ainda que os achados experimentais sejam inconclusivos e preliminares, este trabalho permitiu a padronização da técnica de eletrofisiologia in vivo em animal anestesiado o que abre portas para futuras investigações. / The cholinergic muscarinic system exerts modulatory function over different aspects of cognition and emotion. All five muscarinic receptors subtypes (mAChR), M1 to M5, are expressed at mammals hippocampus and at least two of them are simultaneously activated by most of the drugs, hindering significant advances on the role of each component of this system. The muscarinic toxin 3 (MT3) is a selective antagonist for the M4 subtype, allowing the investigation of the modulatory actions of this receptor over learning, memory and synaptic plasticity. The M4 are G protein coupled receptors (GPCRs) that act through Gi/o triggering inhibitory effects on which cells they are occur. Previous behavioral studies have shown that administration of MT3 soon after aversive task training exerts amnestic effects over memory, while administration prior to recall, leads to facilitation. A possible explanation to these results could be that the local circuits involved on memory consolidation and recall are different in nature. On this perspective, the amnestic effect of MT3 over memory consolidation should be consequence of GABAergic interneurons inhibition suppression; while the effect on recall, should be over glutamatergic synapses modulation. Thereby, the present work, with the objective to investigate how the M4 receptor modulates long-term synaptic plasticity and interacts with the GABAergic system, in vivo electrophysiological approach of anesthetized rats’ hippocampus was applied. Hence, field excitatory postsynaptic potentials (fEPSP) from CA1 were recorded after stimulation of contralateral Schaffer Collateral pathway with drugs infusion 15 min before or after high or low frequency electric stimulation (HFS: 10 trains 0.5 Hz, 20 pulses 100 Hz; LFS: 600 pulses 1 Hz, respectively). Neither MT3 (4.00 μg/μl), bicuculline (0.06 μg/μl), baclofen (0.20 μg/μl) nor vehicle, isolated or combined, changed the baseline evoked response amplitude 15 min after infusion nor the paired-pulse facilitation ratio (PPF). MT3 apparently attenuated, but not significantly, the long-term potentiation (LTP) compared to control (31.8% and 66.0% potentiation 60 min after HFS, respectively). In addition, there was no significant difference between baseline and 60 min after HFS fEPSP amplitude at MT3 group. Bicuculline, although did not abolish LTP neither changed PPF, it did produce a potentiation of only 36.4%. Baclofen induced a potentiation similar to control group. Baclofen administration also significantly reduced PPF compared to baseline. The simultaneous administration of MT3 and bicuculline or baclofen led to a potentiation similar to the control group. MT3 did not show any effect over LTP maintenance when applied 15 min after HFS. Lastly, it was not possible to induce long-term depression (LTD) with the used LFS protocol. Although there was no statistical significance between groups due to the low animal numbers used, data suggest that bicuculline had reduced LTP amplitude. Baclofen did alter PPF and the same was not observed on control group. When bicuculline or baclofen were injected with MT3, those alterations were not observed. These are inconclusive and preliminary results, notwithstanding this work allowed to set up the in vivo electrophysiology technique in anesthetized animals what will provide new tools for future research.

A sinalização muscarínica exerce função modulatória sobre diferentes aspectos da cognição e emoções. Todos os cinco subtipos de receptores muscarínicos (mAChR), M1 a M5, são expressos no hipocampo de mamíferos e são ativados de forma sobreposta pela maioria dos fármacos, dificultando avanços significativos na compreensão da contribuição de cada componente desse sistema. A toxina muscarínica 3 (MT3) é um antagonista seletivo para o subtipo M4, permitindo a investigação das ações modulatórias deste receptor no aprendizado, memória e plasticidade sináptica. Os M4 são receptores acoplados à proteína G (GPCRs) que atuam via Gi/o desencadeando efeitos inibitórios sobre as células em que estão presentes. Estudos comportamentais anteriores indicam que a administração de MT3 imediatamente após o treino em uma tarefa aversiva produz efeito amnéstico, enquanto que a administração antes da evocação, causa facilitação. Uma explicação para estes resultados é que os circuitos locais envolvidos na consolidação e na evocação da memória diferem em sua natureza. Nesse contexto, sugere-se que o efeito amnéstico da MT3 sobre a consolidação seja consequência da supressão da inibição de interneurônios GABAérgicos; enquanto que na evocação, esse efeito se daria sobre as sinapses glutamatérgicas. Assim, no presente trabalho, com o objetivo de investigar como o receptor M4 modula a plasticidade sináptica de longa duração e interage com uma dessas sinalizações, no caso a GABAérgica, utilizou-se a técnica de eletrofisiologia in vivo de hipocampo de ratos anestesiados. Para tanto, foram realizados registros extracelulares do potencial excitatório pós-sináptico de campo (fEPSP) de CA1 evocados por estimulação contralateral da via Colateral de Schaffer com infusão dos fármacos 15 min antes ou depois da estimulação elétrica de alta ou baixa frequência (HFS: 10 trens 0,5 Hz, 20 pulsos 100 Hz; ou LFS: 600 pulsos 1 Hz, respectivamente). MT3 (4,0 μg/μl), bicuculina (0,06 μg/μl), baclofen (0,2 μg/μl) e veículo, isoladamente ou combinados, não alteraram a amplitude da resposta evocada basal ou a facilitação por pulso pareado (FPP) 15 min após a infusão. MT3 aparentemente atenuou, mas não de forma significativa, a potenciação de longa duração (LTP) em relação ao controle (potenciação 60 min após a HFS de 31,8% e 66,0%, respectivamente). Além disso, não houve diferença significativa entre a amplitude do fEPSP no período basal e 60 min após a HFS sob ação da MT3. Bicuculina, embora não tenha abolido a LTP e nem causado alteração na FPP, produziu uma potenciação de apenas 36,4%. Baclofen promoveu uma potenciação semelhante à dos controles. A administração de baclofen também reduziu significativamente a FPP em relação ao basal. A administração conjunta de MT3 com bicuculina ou baclofen promoveu uma potenciação semelhante ao controle. MT3 não apresentou efeito sobre a manutenção da LTP quando aplicada 15 min após a HFS. Por fim, não foi possível induzir a depressão de longa duração (LTD) com o protocolo de LFS utilizado. Embora não tenha ocorrido diferença estatisticamente significativa entre os grupos devido ao baixo número de animais utilizados, os dados sugerem a possibilidade de uma amplitude reduzida da LTP quando da injeção de bicuculina. Baclofen alterou a FPP em relação ao fEPSP basal, o mesmo não tendo sido observado no grupo controle. Com a administração concomitante de MT3, tais alterações deixam de ser identificadas. Ainda que os achados experimentais sejam inconclusivos e preliminares, este trabalho permitiu a padronização da técnica de eletrofisiologia in vivo em animal anestesiado o que abre portas para futuras investigações. / The cholinergic muscarinic system exerts modulatory function over different aspects of cognition and emotion. All five muscarinic receptors subtypes (mAChR), M1 to M5, are expressed at mammals hippocampus and at least two of them are simultaneously activated by most of the drugs, hindering significant advances on the role of each component of this system. The muscarinic toxin 3 (MT3) is a selective antagonist for the M4 subtype, allowing the investigation of the modulatory actions of this receptor over learning, memory and synaptic plasticity. The M4 are G protein coupled receptors (GPCRs) that act through Gi/o triggering inhibitory effects on which cells they are occur. Previous behavioral studies have shown that administration of MT3 soon after aversive task training exerts amnestic effects over memory, while administration prior to recall, leads to facilitation. A possible explanation to these results could be that the local circuits involved on memory consolidation and recall are different in nature. On this perspective, the amnestic effect of MT3 over memory consolidation should be consequence of GABAergic interneurons inhibition suppression; while the effect on recall, should be over glutamatergic synapses modulation. Thereby, the present work, with the objective to investigate how the M4 receptor modulates long-term synaptic plasticity and interacts with the GABAergic system, in vivo electrophysiological approach of anesthetized rats’ hippocampus was applied. Hence, field excitatory postsynaptic potentials (fEPSP) from CA1 were recorded after stimulation of contralateral Schaffer Collateral pathway with drugs infusion 15 min before or after high or low frequency electric stimulation (HFS: 10 trains 0.5 Hz, 20 pulses 100 Hz; LFS: 600 pulses 1 Hz, respectively). Neither MT3 (4.00 μg/μl), bicuculline (0.06 μg/μl), baclofen (0.20 μg/μl) nor vehicle, isolated or combined, changed the baseline evoked response amplitude 15 min after infusion nor the paired-pulse facilitation ratio (PPF). MT3 apparently attenuated, but not significantly, the long-term potentiation (LTP) compared to control (31.8% and 66.0% potentiation 60 min after HFS, respectively). In addition, there was no significant difference between baseline and 60 min after HFS fEPSP amplitude at MT3 group. Bicuculline, although did not abolish LTP neither changed PPF, it did produce a potentiation of only 36.4%. Baclofen induced a potentiation similar to control group. Baclofen administration also significantly reduced PPF compared to baseline. The simultaneous administration of MT3 and bicuculline or baclofen led to a potentiation similar to the control group. MT3 did not show any effect over LTP maintenance when applied 15 min after HFS. Lastly, it was not possible to induce long-term depression (LTD) with the used LFS protocol. Although there was no statistical significance between groups due to the low animal numbers used, data suggest that bicuculline had reduced LTP amplitude. Baclofen did alter PPF and the same was not observed on control group. When bicuculline or baclofen were injected with MT3, those alterations were not observed. These are inconclusive and preliminary results, notwithstanding this work allowed to set up the in vivo electrophysiology technique in anesthetized animals what will provide new tools for future research.

La moelle épinière assure la transmission des messages nerveux entre l’encéphale et le reste du corps et assure la coordination des mouvements rythmiques de la locomotion. Elle est constituée d’un grand nombre de types différents d’interneurones et de neurones moteurs, organisés en circuits neuronaux. Les circuits impliqués dans la transmission des informations sensorielles et dans les mouvements des membres sont localisés respectivement dans les parties dorsale et ventrale de la moelle épinière. Les mécanismes moléculaires contrôlant la spécification de ces différents types de neurones dans la moelle épinière restent actuellement mal connus. Au cours de mon travail de thèse, je me suis intéressée à la famille des gènes Prdm (PR Domain containing methyltransferase). Ces gènes sont conservés évolutivement. Ils codent pour des facteurs de transcription jouant des rôles importants dans le développement embryonnaire et sont fréquemment impliqués dans des maladies chez l’Homme. Ces facteurs sont caractérisés par la présence d’un domaine PR semblable au domaine SET trouvé dans des protéines à activité histone méthyltransférase et d’un nombre variable de doigts à zinc. Je me suis focalisée essentiellement sur les gènes Prdm12 et Prdm13, des gènes exprimés de manière précoce et localisés dans le système nerveux en développement et dont la fonction était totalement inconnue. Nos résultats ont montré que l’expression de Prdm12 dans la partie ventrale de la moelle épinière est dépendante de l’acide rétinoïque et du facteur de transcription Pax6 et que Prdm12 est restreint au domaine p1 via l’action répressive des facteurs de transcription Dbx1 et Nkx6 exprimés dans les domaines de progéniteurs adjacents. Prdm12 fonctionne comme déterminant de la destinée des interneurones V1, des interneurones impliqués dans le contrôle des mouvements de la locomotion et essentiels à la survie des neurones moteurs. Prdm12 agirait en réprimant, probablement directement, l’expression des gènes Dbx1 et Nkx6.1/2, ses domaines PR et ZnF étant tous deux requis pour son activité. Nos données indiquent aussi que Prdm13, qui est exprimé dans la partie dorsale de la moelle épinière, constitue une cible directe du complexe Ptf1a-Rbpj et qu’il est requis en aval de Ptf1a pour une balance correcte des neurones glutamatergiques et GABAergiques. Elles suggèrent que Prdm13 fonctionnerait, au moins en partie, en bloquant l’activité d’autres facteurs proneuraux tels que Ngn2 (Neurog2) ou Ascl1 (Mash1) présents dans la partie dorsale de la moelle épinière et qui induisent une destinée excitatrice glutamatergique. / Doctorat en Sciences / info:eu-repo/semantics/nonPublished

No description available.

Caspr2 est une molécule d'adhérence impliquée dans diverses pathologies neurologiques telles que l'autisme et l'encéphalite limbique (EL). Les mécanismes pathogéniques restent inconnus. Caspr2 est associé aux canaux potassiques Kv1.1/1.2 aux juxtaparanoeuds et au segment initial (SI). Dans un premier article publié dans Front. Cell. Neurosci. (2015), nous avons mis en évidence que les autoanticorps anti-Caspr2 issus de patients atteints d'EL ciblent majoritairement les neurones GABAergiques. Caspr2 est localisé au niveau des axones et des terminaisons présynaptiques inhibitrices dans les neurones d'hippocampe en culture. De plus, nous avons généré une chimère Caspr2-Fc soluble qui a permis d’identifier TAG-1 comme récepteur de Caspr2 localisé au niveau du compartiment somato-dendritique postsynaptique. Les neurones incubés avec des IgGs de patients, présentent une densité diminuée des clusters de Géphyrine marqueur des post-synapses inhibitrices. Ces anticorps sont d'isotype IgG4 et reconnaissent le plus communément des épitopes de la région Discoïdine-LaminineG1. Un blocage fonctionnel de Caspr2 au niveau synaptique permettrait de comprendre l'hyperexcitabilité associée à l'EL. Dans un second article en préparation, nous avons étudié la régulation de l’expression de Caspr2 au SI. Nous avons utilisé différentes constructions et identifié les domaines LamineG2-EGF1 extracellulaires de Caspr2 requis pour son expression axonale. De plus, les domaines cytoplasmiques de liaison aux protéines 4.1B et PDZ sont impliqués dans la rétention de Caspr2 et MPP2 au SI. Notablement, l'expression de TAG-1 ou ADAM22 induit des effets opposés sur l'expression de Caspr2 au SI. / Caspr2 is a cell adhesion molecule associated with neurologic diseases, such as autism spectrum disorders and limbic encephalitis. The underlying pathogenic mechanisms are still unknown. Caspr2 is associated with the voltage-gated potassium channels Kv1.1/1.2 localized at the axon initial segment (AIS) and the juxtaparanodes in myelinated axons. In a first paper published in Front. Cell. Neurosci. (2015), we characterized anti-Caspr2 autoantibodies from limbic encephalitis (LE) patients and showed that these autoantibodies preferentially targeted GABAergic neurons. Caspr2 was localized along axons and at the presynaptic terminals of inhibitory neurons in hippocampal cultures. Next, we generated a soluble Caspr2-Fc chimera to identify TAG-1 as a receptor for Caspr2 localized at the somato-dendritic compartment and post-synapses. We determined that neurons displayed decreased synaptic gephyrin clusters when incubated with anti-Caspr2 IgGs from LE patients. The autoantibodies mainly bound the N-terminal Discoidin-LamininG1 domains and were of the IgG4 isotype. They may exert functional blocking activity on inhibitory connections underlying the hyperexcitability linked with LE. In a second article in preparation, we examined the regulated expression of Caspr2 at the AIS using deletion and reporter constructs. We mapped the LamininG2 and EGF1 modules in the ectodomain as implicated in the axonal distribution of Caspr2 and the cytoplasmic motifs for binding to 4.1B and PDZ proteins as implicated in Caspr2 AIS retention together with MPP2. Strikingly, co-expression with TAG-1 and ADAM22 induced opposite effects on AIS Caspr2 distribution.

Les récepteurs métabotropiques du glutamate (mGluRs) sont des récepteurs couplés aux protéines G (RCPGs) modulant la transmission synaptique au sein du système nerveux central. D'un point de vue structural, ils ont la particularité de posséder un large domaine extracellulaire, le Venus Flytrap (VFT), où se lie leur ligand endogène, le glutamate. Leur domaine transmembranaire à 7 hélices, commun à tous les RCPGs, est connu pour être la cible d'une nouvelle classe de molécules à visée thérapeutique, les modulateurs allostériques. Au contraire, le VFT est le siège du développement de ligands compétitifs du glutamate et peu de choses sont connues quant à l'existence de modulateurs allostériques du VFT. Des études récentes ont mis en évidence une sensibilité des mGluRs aux ions extracellulaires et en particulier au chlore (Cl-), sans que son site de liaison ne soit identifié. Dans ce contexte, ce travail de thèse explore la possibilité d'une modulation allostérique endogène des mGluRs par les ions Cl-, en identifiant leur(s) site(s) de liaison(s) et leur effet sur la dynamique conformationnelle et la fonction des récepteurs. En combinant une approche pharmacologique, biophysique basée sur la technique de FRET, et la modélisation, nous avons tout d'abord confirmé que le Cl- potentialise l'action du glutamate sur tous les mGluRs et qu'il favorise la conformation active des récepteurs en se liant au niveau du VFT. Les mGluRs présentent également une sensibilité différente au Cl-, mGlu4 étant le plus sensible et mGlu2 le moins. Ceci s'explique notamment par le nombre de sites fonctionnels, tous les mGluRs dont mGlu4 possédant 2 sites par monomère à l'exception de mGlu2 qui n'en possède qu'un, en raison d'une mutation « clé » d'une sérine en aspartate dans le lobe 1 du VFT. D'autre part, le récepteur mGlu3 est apparu comme un cas particulier ayant une sensibilité accrue au Cl-, son domaine VFT cumulant la présence et l'orientation adéquate d'acides aminés formant un « verrou » Cl-, qui favorise de manière drastique la conformation active et une activité basale élevée de ce récepteur. Enfin, la modélisation de la variation de la concentration extracellulaire en Cl- lors d'une activité synaptique GABAergique est compatible avec une modulation des mGluRs les plus sensibles. En conclusion, le Cl- est un modulateur allostérique endogène des mGluRs et l'exploitation de ses sites de liaison au sein du VFT pourrait permettre le développement de nouveaux agents thérapeutiques. / Metabotropic glutamate receptors (mGluRs) are G coupled-protein receptors (GPCRs) playing key roles in synaptic transmission in the central nervous system. They display a large extracellular domain, the Venus Flytrap (VFT) where the endogenous ligand, glutamate, binds. Their 7 transmembrane helices spanning domain, common to all GPCRs, is known to be the target of new therapeutic compounds, called allosteric modulators. In contrast, VFT domain is used to develop glutamate competitive ligands and there are only few data about allosteric modulators targeting the VFT. Recent studies have shown mGluRs are sensitive to extracellular ions, particularly to chloride (Cl-), although its binding site has not been elucidated. This thesis work explores the possibility of an endogenous allosteric modulation of mGluRs by Cl-, aiming to delineate its binding site(s) and its effect on receptor conformational dynamics and function. Using pharmacological, FRET based biophysical approaches and modelling, we have first confirmed that Cl- potentiates glutamate action in all mGluRs and that this ion favors agonist induced active conformation by binding to the VFT. mGluRs are also differently sensitive to Cl-, mGlu4 being the most and mGlu2 the least. This difference is notably explained by the number of Cl- functional sites within the VFT, all mGluRs including mGlu4 displaying 2 sites per monomer whereas mGlu2 has only 1 site due to a serine-aspartate “key” mutation in VFT lobe 1. Besides, mGlu3 receptor appears to be a “special case”, as this receptor is highly sensitive to Cl- because its VFT domain is carrying amino acids creating a “Cl- lock”, which dramatically favors active conformation and a high level of basal activity. Finally, modelling of extracellular Cl- concentration variations in a GABAergic synapse is compatible with a modulation of the most sensitive mGluRs. In conclusion, Cl- is an endogenous allosteric modulator of mGluRs and exploiting its binding sites may yield to the development of innovative therapeutic tools.

Toxoplasma gondii is an obligate intracellular parasite that infects virtually all warm-blooded organisms. Systemic dissemination of T. gondii in the organism can cause life-threatening infection that manifests as Toxoplasma encephalitis in immune-compromised patients. In addition, mounting evidence from epidemiological studies indicates a link between chronic Toxoplasma infection and mental disorders. To better understand the pathogenesis of toxoplasmosis, basic knowledge on the host-parasite interactions and the dissemination mechanisms are essential. Previous findings have established that, upon infection with T. gondii, dendritic cells (DCs) and microglia exhibit enhanced migration, which was termed the hypermigratory phenotype. As a result of this enhanced migration, DCs and microglia are used as vehicle cells for dissemination (‘Trojan horse’) which potentiates dissemination of T. gondii in mice. However, the precise mechanisms behind the hypermigratory phenotype remained unknown. In this thesis, we characterized host-parasite interactions upon infection with T. gondii and investigated the basic mechanisms behind the hypermigratory phenotype of T. gondii-infected DCs and microglia. In paper I, we observed that upon infection with T. gondii, DCs underwent rapid morphological changes such as loss of adhesiveness and podosomes, with integrin redistribution. These rapid morphological changes were linked to hypermotility and were induced by active invasion of T. gondii within minutes. T. gondii-infected DCs exhibited up-regulation of the C-C chemokine receptor CCR7 and chemotaxis towards the CCR7 chemotactic cue, CCL19. In paper II, we developed a 3-dimensional migration assay in a collagen matrix, which allowed us to characterize the hypermigratory phenotype in a more in vivo-like environment. The migration of T. gondii-infected DCs exhibited features consistent with integrin-independent amoeboid type of migration. T. gondii-induced hypermigration of DCs was further potentiated in the presence of CCL19 in a 3D migration assay. In paper III, we identified a parasite effector molecule, a Tg14-3-3 protein derived from parasite secretory organelles. Tg14-3-3 was sufficient to induce the hypermigratory phenotype. Transfection with Tg14-3-3-containing fractions or recombinant Tg14-3-3 protein induced the hypermigratory phenotype in primary DCs and in a microglial cell line. In addition, Tg14-3-3 localized in the parasitophorous vacuolar space and host 14-3-3 proteins were rapidly recruited around the parasitophorous vacuole. In paper IV, we found that mouse DCs dominantly express the L-type voltage-dependent calcium channel, Cav1.3. Cav1.3 was linked to the GABAergic signaling-induced hypermigratory phenotype. Pharmacological inhibition of Cav1.3 and knockdown of Cav1.3 abolished the hypermigratory phenotype in T. gondii infected DCs. Blockade of voltage-dependent calcium channels reduced the dissemination of T. gondii in a mouse model. In paper V, we showed that microglia, resident immune cells in the brain, also exhibited rapid morphological changes and hypermotility upon infection with T. gondii. However, an alternative GABA synthesis pathway was shown to be involved in the hypermigratory phenotype in microglia. In summary, this thesis describes novel host-parasite interactions, including host cell migratory responses and key molecular mechanisms that mediate the hypermigratory phenotype. The findings define a novel motility-related signaling axis in DCs. Thus, T. gondii employs GABAergic non-canonical pathways to hijack host cell migration and facilitate dissemination. We believe that these findings represent a significant step forward towards a better understanding of the pathogenesis of T. gondii infection. / <p>At the time of the doctoral defense, the following papers were unpublished and had a status as follows: Paper 4: Manuscript. Paper 5: Manuscript.</p>

La sclérose latérale amyotrophique (SLA) est une maladie neurodégénérative fatale caractérisée par une perte progressive et sélective des neurones moteurs. La SLA est incurable et il n’existe aucun traitement efficace pour les personnes atteintes de cette maladie. Environ 90% des cas sont sporadiques tandis que 10% sont familiaux, et les patients décèdent généralement deux à cinq ans après l'apparition des premiers symptômes. De nombreuses anomalies génétiques sont associées à la SLA, incluant des mutations dans les protéines FUS, C9orf72, SOD-1 et TDP-43. Le laboratoire a développé un modèle transgénique de Caenorhabditis elegans surexprimant la protéine humaine mutante TDP-43(Q331K) dans les neurones moteurs GABAergiques. Nous avons également obtenu par mutagénèse et CRISPR-Cas9 des modèles physiologiquement représentatifs du nématode basés sur des mutations dans tdp-1, l'orthologue de TARDBP chez le C. elegans. L'objectif est de caractériser ces modèles et de déterminer s'ils peuvent récapituler certains aspects phénotypiques clés de la SLA, tels que des déficits moteurs et une neurodégénérescence dépendante de l'âge générant une paralysie. L’hypothèse est que le modèle TDP-1 pourra refléter plus précisément l’expression physiologique du gène dans la maladie humaine grâce à la mutation dans un gène endogène, l’absence de surexpression et l’expression ubiquitaire de la protéine TDP-1. Les résultats montrent que les modèles TDP-43/TDP-1 ont des déficits moteurs, une transmission synaptique altérée et une neurodégénérescence liée à l’âge. Cependant, seule la mutation dans TDP-43 semble avoir un effet sur la durée de vie. Ces modèles procurent différentes expressions physiologiques des protéines mutantes et donc, des phénotypes de niveaux d'intensité variables. Ils constitueront des outils utiles pour élucider de nouveaux mécanismes pathogéniques de la SLA ainsi que de bons candidats pour le criblage de médicaments et le développement de stratégies thérapeutiques. / Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive and selective loss of motor neurons. ALS is incurable and there are no effective treatments available for people living with the disease. About 90% of the cases are sporadic whereas 10% are familial, and patients usually die two to five years after symptom onset. Many gene defects are associated with ALS, including mutations in genes encoding FUS, C9orf72, SOD-1 and TDP-43 proteins. We have developed a transgenic Caenorhabditis elegans model expressing human mutant TDP-43(Q331K) in GABAergic motor neurons. We have also obtained by mutagenesis and CRISPR-Cas9 physiologically accurate models based on mutations in tdp-1, the C. elegans ortholog of TARDBP. Our objective is to characterize these models and determine if they can recapitulate key aspects of the disease such as motor deficits and age-dependent neurodegeneration causing paralysis. We believe that the TDP-1 model will reflect more precisely the physiological expression of the gene in the human disease because of its mutation in an endogenous gene, the absence of overexpression and ubiquitous protein expression. Our results show that both TDP-43 and TDP-1 models have motor deficits, synaptic transmission impairments and age-dependent neurodegeneration. However, only the TDP-43 mutation seems to have an effect on lifespan. These models provide different physiological expression of mutant proteins and thus phenotypes of varying intensity levels. They will be useful tools to elucidate new pathogenic mechanisms of ALS as well as being good candidates for drug screening and developing therapeutic strategies.